Cargando…
Why we should not recommend or offer fluvoxamine to COVID-19 patients?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780092/ https://www.ncbi.nlm.nih.gov/pubmed/36550263 http://dx.doi.org/10.1007/s00228-022-03447-3 |
| _version_ | 1784856769341685760 |
|---|---|
| author | Trkulja, Vladimir |
| author_facet | Trkulja, Vladimir |
| author_sort | Trkulja, Vladimir |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9780092 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97800922022-12-23 Why we should not recommend or offer fluvoxamine to COVID-19 patients? Trkulja, Vladimir Eur J Clin Pharmacol Correspondence Springer Berlin Heidelberg 2022-12-23 2023 /pmc/articles/PMC9780092/ /pubmed/36550263 http://dx.doi.org/10.1007/s00228-022-03447-3 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correspondence Trkulja, Vladimir Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title | Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title_full | Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title_fullStr | Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title_full_unstemmed | Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title_short | Why we should not recommend or offer fluvoxamine to COVID-19 patients? |
| title_sort | why we should not recommend or offer fluvoxamine to covid-19 patients? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780092/ https://www.ncbi.nlm.nih.gov/pubmed/36550263 http://dx.doi.org/10.1007/s00228-022-03447-3 |
| work_keys_str_mv | AT trkuljavladimir whyweshouldnotrecommendorofferfluvoxaminetocovid19patients |